InsiderSignal.AI

InsiderSignal.ai

XGN - Exagen Inc.

Insider Sale by Aballi John (Pres, CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

2 days ago, Aballi John, serving as Pres, CEO at Exagen Inc. (XGN), sold 15,698 shares at $3.62 per share, for a total transaction value of $56,827.00. Following this transaction, Aballi John now holds 730,235 shares of XGN.

This sale represents a 2.00% decrease in Aballi John's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Tuesday, March 3, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, March 4, 2026, 1 day after the trade was made.

Exagen Inc. operates in the HEALTHCARE sector, specifically within the DIAGNOSTICS & RESEARCH industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Aballi John

Pres, CEO

John Aballi is the President, Chief Executive Officer, and Director of Exagen Inc. (NASDAQ: XGN), a life sciences company focused on autoimmune condition diagnosis and management, a role he has held since October 16, 2022.[[1]](https://fintool.com/app/research/companies/XGN/people/john-aballi)[[2]](https://www.biospace.com/exagen-announces-appointment-of-john-aballi-as-ceo)[[6]](https://exagen.com/leadership/) Aged 40 as of April 2025, Aballi holds a B.S. in Biochemistry and Cell Biology, a B.A. in Economics from UC San Diego, and an MBA from California Baptist University.[[1]](https://fintool.com/app/research/companies/XGN/people/john-aballi)[[2]](https://www.biospace.com/exagen-announces-appointment-of-john-aballi-as-ceo) Aballi brings over 15 years of experience in clinical diagnostics, with prior roles including SVP and General Manager of Urology & CLIA COO at Veracyte, Inc., where he expanded the urology franchise to over $120M in annual revenue,[[1]](https://fintool.com/app/research/companies/XGN/people/john-aballi)[[2]](https://www.biospace.com/exagen-announces-appointment-of-john-aballi-as-ceo) and SVP & COO at Decipher Biosciences, driving revenue from $12.6M in 2018 to $39M in 2020 ahead of its $600M acquisition by Veracyte.[[2]](https://www.biospace.com/exagen-announces-appointment-of-john-aballi-as-ceo) Earlier positions include Head of Operations at Molecular Stethoscope and senior roles at Genoptix.[[1]](https://fintool.com/app/research/companies/XGN/people/john-aballi)[[2]](https://www.biospace.com/exagen-announces-appointment-of-john-aballi-as-ceo) Under his leadership at Exagen, 2024 revenue grew to $55.6M from $52.5M in 2023, gross margins expanded to 59.5%, and net loss narrowed to $(15.1)M from $(23.7)M.[[1]](https://fintool.com/app/research/companies/XGN/people/john-aballi)

View full insider profile →

Trade Price

$3.62

Quantity

15,698

Total Value

$56,827.00

Shares Owned

730,235

Trade Date

Tuesday, March 3, 2026

2 days ago

SEC Filing Date

Wednesday, March 4, 2026

Filed 1 day after trade

HEALTHCAREDIAGNOSTICS & RESEARCH

About Exagen Inc.

Company Overview

No company information available
View news mentioning XGN

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4495151

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime